A randomized, active-controlled, multi-centric, phase-II clinical study to assess safety and immunogenicity of a fully liquid DTwP-HepB-IPV-Hib hexavalent vaccine (HEXASIIL®) in Indian toddlers.

Autor: Sharma H; Dept. of Clinical Research, Serum Institute of India Pvt. Ltd., Pune, India. Electronic address: drhjs@seruminstitute.com., Parekh S; Dept. of Clinical Research, Serum Institute of India Pvt. Ltd., Pune, India., Pujari P; Dept. of Clinical Research, Serum Institute of India Pvt. Ltd., Pune, India., Shewale S; Dept. of Clinical Research, Serum Institute of India Pvt. Ltd., Pune, India., Desai S; Dept. of Clinical Research, Serum Institute of India Pvt. Ltd., Pune, India., Kawade A; Dept. of Pediatrics, KEM Hospital Research Centre, Vadu, Pune, India., Lalwani S; Dept. of Pediatrics, Bharati Vidyapeeth (Deemed to be University) Medical College & Hospital, Pune, India., Ravi MD; Dept. of Pediatrics, JSS Hospital, Mysuru, India., Ramanan PV; Dept. of Pediatrics, Sri Ramachandra Hospital, Chennai, India., Kamath V; Dept. of Community Medicine, Kasturba Medical College at Dr TMA Pai Hospital, Udupi, India., Agarwal A; Dept. of Pediatrics, Maulana Azad Medical College & Lok Nayak Hospital, New Delhi, India., Dogar V; Dept. of Quality Control, Serum Institute of India Pvt. Ltd., Pune, India., Gautam M; Dept. of Quality Control, Serum Institute of India Pvt. Ltd., Pune, India., Jaganathan KS; Production Department, Serum Institute of India Pvt. Ltd., Pune, India., Kumar R; Production Department, Serum Institute of India Pvt. Ltd., Pune, India., Sharma I; Production Department, Serum Institute of India Pvt. Ltd., Pune, India., Gairola S; Dept. of Quality Control, Serum Institute of India Pvt. Ltd., Pune, India.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2024 Dec 02; Vol. 42 (26), pp. 126380. Date of Electronic Publication: 2024 Sep 19.
DOI: 10.1016/j.vaccine.2024.126380
Abstrakt: Background: Combination vaccines are effective in simplifying complex vaccination schedules involving multiple vaccines. A fully liquid hexavalent diphtheria (D)-tetanus (T)-whole-cell pertussis (wP)- hepatitis B (HepB)-inactivated poliovirus (IPV)-Haemophilus influenzae b (Hib) vaccine (HEXASIIL®), manufactured by Serum Institute of India Pvt. Ltd. was tested for safety and immunogenicity following booster vaccination.
Methods: This was a phase-II/III, open label, multicentric, controlled trial in toddlers (phase II) and infants (phase III) in India. This manuscript presents results of phase II. Healthy toddlers aged 12-24 months were randomized (1:1) to receive a 0.5 ml booster dose of HEXASIIL® or comparator Pentavac SD + Poliovac, intramuscularly and followed for 28 days for safety assessment. Blood samples were collected pre-vaccination and 28 days post-vaccination to assess immunogenicity. Descriptive summary statistics were provided for safety and immunogenecity analyses.
Results: A total of 223 subjects were randomized. One subject droped out prior to dosing, due to consent withdrawal. Thus, 222 subjects received study vaccine (110 HEXASIIL® and 112 comparator). Frequency of solicited adverse events was comparable between HEXASIIL® and comparator (85.5 % vs 90.2 %). Most local and systemic solicited AEs were mild to moderate in severity. All events resolved completely without any sequelae and none led to subject discontinuation. No vaccine related serious AE was reported. Post vaccination, seroprotection rates against tetanus, Hib and polio type 1 and 3 were 100 % in both the groups. Seroprotection rates for diphtheria (99.1 % vs 100 %) and polio type 2 (98.2 % vs 100 %) were observed in HEXASIIL® and comparator group, respectively. For Hepatitis B, seroprotection was >99 % in both groups. Seroconversion observed for Bordetella Pertussis (94.5 % vs 95.4 %) and Pertussis Toxin (77.1 % vs 87.2 %) in HEXASIIL® and comparator group, respectively.
Conclusion: HEXASIIL® vaccine was found to be safe and immunogenic in toddlers and supported its further clinical development in infants. Clinical Trial Registration - CTRI/2019/11/022052.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The authors HS, SP, PP, SS, SD, MG, VD, JK, RK, IS and SG are employees of Serum Institute of India Pvt. Ltd. AK, SL, MDR, PVR, VK, and AA are declare no financial and non-financial relationships and activities and no conflicts of interest.
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE